Actively Recruiting
Study to Evaluate How LY3537031 Is Processed and Its Safety in People With Normal or Impaired Liver Function
Led by Eli Lilly and Company · Updated on 2026-09-30
32
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying LY3537031 to understand how it behaves in the body of participants with different levels of liver function, including normal, mild, moderate, and severe impairment. This Phase 1 study aims to measure how much of LY3537031 enters the bloodstream and how long it takes to be eliminated, while also assessing the drugs safety and tolerability. Participants will receive a single dose of LY3537031 administered under the skin subcutaneously. The study includes four groups based on liver function those with normal liver function and those with mild, moderate, or severe hepatic impairment. Each group receives the study drug once, and the study follows up with participants for up to 8 weeks to collect data. During the study, participants will undergo screening including medical history and physical exams to confirm eligibility. Researchers will measure the drug concentration in the blood over time, focusing on the area under the concentration-time curve and the maximum concentration reached. Safety is monitored throughout the study. Participation lasts up to 8 weeks from the dose until study completion.
CONDITIONS
Brief Title
A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
P
Physicians interested in becoming principal investigators please contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here